TABLE 3.
The associations of demographic and clinical characteristics with plasma endothelin-1 (ET-1) concentrations by cocaine use status, robust regression
Univariate model | Final multivariate model | ||||||
---|---|---|---|---|---|---|---|
Characteristics | Estimate | SE | P value | Estimate | SE | P value | |
All | |||||||
Age | 0.012 | 0.003 | <0.001 | 0.012 | 0.003 | <0.001 | |
Current cigarette smoking | 0.317 | 0.060 | <0.001 | 0.324 | 0.059 | <0.001 | |
Years of cigarette smoking | 0.012 | 0.002 | <0.001 | ||||
Years of alcohol use | 0.005 | 0.002 | 0.040 | ||||
Long-term cocaine use | 0.239 | 0.062 | <0.001 | ||||
Body mass index (BMI, kg/m2) | −0.007 | 0.005 | 0.149 | ||||
Duration of PI therapy (months) | 0.001 | 0.001 | 0.026 | ||||
Duration of NRTI therapy (months) | 0.002 | 0.001 | 0.009 | ||||
Duration of NNRTI therapy (months) | 0.002 | 0.001 | 0.068 | ||||
Cocaine use | |||||||
Age | 0.017 | 0.006 | 0.003 | 0.024 | 0.006 | <0.001 | |
Current cigarette smoking | 0.275 | 0.089 | 0.002 | 0.331 | 0.086 | <0.001 | |
Years of cigarette smoking | 0.011 | 0.003 | 0.000 | ||||
Total cholesterol (mg/dL) | −0.002 | 0.001 | 0.062 | −0.002 | 0.001 | 0.049 | |
Duration of PI therapy (months) | 0.001 | 0.001 | 0.081 | ||||
Duration of NRTI therapy (months) | 0.002 | 0.001 | 0.027 | ||||
Duration of NNRTI therapy (months) | 0.004 | 0.001 | 0.003 | 0.003 | 0.001 | 0.004 | |
Cocaine non-use | |||||||
Current cigarette smoking | 0.310 | 0.080 | <0.001 | 0.609 | 0.164 | <0.001 | |
Years of cigarette smoking | 0.006 | 0.003 | 0.058 | ||||
Systolic BP (mm Hg) | −0.004 | 0.002 | 0.095 | ||||
HDL–C (mg/dL) | −0.005 | 0.002 | 0.054 | ||||
CD4 count at baseline (cells/mm3) | −0.0006 | 0.0003 | 0.065 | −0.001 | 0.000 | 0.008 |